Online first
Original Article
Published online: 2024-05-14

open access

Page views 134
Article views/downloads 66
Get Citation

Connect on Social Media

Connect on Social Media

Correlations between soluble ST2 concentration and the nutritional status in patients with heart failure with reduced ejection fraction — cross-sectional study

Marta Kałużna-Oleksy1, Filip Waśniewski1, Magdalena Szczechla1, Filip Sawczak1, Agata Kukfisz1, Helena Krysztofiak2, Katarzyna Przytarska1, Ewa Straburzyńska-Migaj1, Magdalena Dudek1
Pubmed: 38742746


Background: Heart failure (HF) is a global problem that stimulates research on markers associated with the diagnosis and course of the disease. Soluble suppression of tumorigenicity-2 (sST2) is a receptor for interleukin-33 and is associated with increased mortality rates in HF patients. Malnutrition in HF is also connected with inflammation and is associated with worse prognosis. The present study aimed to evaluate the relationship between sST2 concentration and the nutritional status of patients with HF with reduced ejection fraction (HFrEF).

Material and methods: 138 patients with HFrEF were enrolled in this cross-sectional study. Nutritional status was assessed using Geriatric Nutritional Risk Index (GNRI) and Controlling Nutritional Status (CONUT). The mean age was 53.6 ± 10.8 years.

Results: In the group with sST2 > 32.9 ng/mL, the GNRI score was higher and the associated risk of malnutrition was more common (29% vs. 12%; p = 0.011). Coherently in the group with sST2 > 32.9 ng/mL the median CONUT score was worse (2 [IQR 1–3] vs. 1 [IQR 0–2]; p = 0.0016) and the risk of malnutrition defined by this tool was also more prevalent (p = 0.0079). This relationship was independent of the concentration of natriuretic peptides, age and sex.

Conclusions: According to available research, this research is the first study showing that sST2 concentration is related with nutritional status in HFrEF patients. sST2 may help to evaluate the necessity for nutritional intervention in HFrEF patients.

Article available in PDF format

View PDF Download PDF file


  1. McDonagh TA, Metra M, Adamo M, et al. Authors/Task Force Members:, ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022; 24(1): 4–131.
  2. Sarhene M, Wang Y, Wei J, et al. Biomarkers in heart failure: the past, current and future. Heart Fail Rev. 2019; 24(6): 867–903.
  3. Kuster N, Huet F, Dupuy AM, et al. Multimarker approach including CRP, sST2 and GDF-15 for prognostic stratification in stable heart failure. ESC Heart Fail. 2020; 7(5): 2230–2239.
  4. Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002; 106(23): 2961–2966.
  5. Bartunek J, Delrue L, Van Durme F, et al. Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol. 2008; 52(25): 2166–2174.
  6. Kotsiou OS, Gourgoulianis KI, Zarogiannis SG. IL-33/ST2 Axis in Organ Fibrosis. Front Immunol. 2018; 9: 2432.
  7. Yang Q, Kong L, Huang W, et al. Osthole attenuates ovalbumin‑induced lung inflammation via the inhibition of IL‑33/ST2 signaling in asthmatic mice. Int J Mol Med. 2020; 46(4): 1389–1398.
  8. Chen Bo, Geng J, Gao SX, et al. Eplerenone modulates interleukin-33/sST2 signaling and IL-1β in left ventricular systolic dysfunction after acute myocardial infarction. J Interferon Cytokine Res. 2018; 38(3): 137–144.
  9. Dudek M, Kałużna-Oleksy M, Migaj J, et al. Clinical value of soluble ST2 in cardiology. Adv Clin Exp Med. 2020; 29(10): 1205–1210.
  10. Zhu J, Ruan Z, Zhu Li. Correlation between serum LP-PLA2 and sST2 levels and the condition of patients with acute heart failure and their prognostic value. Evid Based Complement Alternat Med. 2021; 2021: 8267776.
  11. Boisot S, Beede J, Isakson S, et al. Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. J Card Fail. 2008; 14(9): 732–738.
  12. Demissei BG, Cotter G, Prescott MF, et al. A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial. Eur J Heart Fail. 2017; 19(8): 1001–1010.
  13. van Vark LC, Lesman-Leegte I, Baart SJ, et al. TRIUMPH Investigators. Prognostic value of serial ST2 measurements in patients with acute heart failure. J Am Coll Cardiol. 2017; 70(19): 2378–2388.
  14. Sun Y, Feng Li, Hu B, et al. Prognostic value of β1 adrenergic receptor autoantibody and soluble suppression of tumorigenicity-2 in patients with acutely decompensated heart failure. Front Cardiovasc Med. 2022; 9: 821553.
  15. Ip C, Luk KS, Yuen VL, et al. International Health Informatics Study (IHIS) Network. Soluble suppression of tumorigenicity 2 (sST2) for predicting disease severity or mortality outcomes in cardiovascular diseases: A systematic review and -analysis. Int J Cardiol Heart Vasc. 2021; 37: 100887.
  16. Dudek M, Kałużna-Oleksy M, Migaj J, et al. sST2 and heart failure - clinical utility and prognosis. J Clin Med. 2023; 12(9).
  17. Bahuleyan CG, Alummoottil GK, Abdullakutty J, et al. Prognostic value of soluble ST2 biomarker in heart failure patients with reduced ejection fraction - A multicenter study. Indian Heart J. 2018; 70 Suppl 1(Suppl 1): S79–S84.
  18. Gruson D, Lepoutre T, Ahn SA, et al. Increased soluble ST2 is a stronger predictor of long-term cardiovascular death than natriuretic peptides in heart failure patients with reduced ejection fraction. Int J Cardiol. 2014; 172(1): e250–e252.
  19. Friões F, Lourenço P, Laszczynska O, et al. Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction. Clin Res Cardiol. 2015; 104(6): 491–499.
  20. Wang Z, Pan X, Xu H, et al. Serum soluble ST2 is a valuable prognostic biomarker in patients with acute heart failure. Front Cardiovasc Med. 2022; 9: 812654.
  21. Januzzi JL, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. J Am Coll Cardiol. 2007; 50(7): 607–613.
  22. Zhang R, Zhang Y, Zhang J, et al. The prognostic value of plasma soluble ST2 in hospitalized Chinese patients with heart failure. PLoS One. 2014; 9(10): e110976.
  23. Adejumo AC, Adejumo KL, Adegbala OM, et al. Protein-Energy malnutrition and outcomes of hospitalizations for heart failure in the USA. Am J Cardiol. 2019; 123(6): 929–935.
  24. Qian Y, Qian X, Shen M, et al. Effect of malnutrition on outcomes in patients with heart failure: A large retrospective propensity score-matched cohort study. Nutr Clin Pract. 2022; 37(1): 130–136.
  25. Itagaki T, Motoki H, Otagiri K, et al. Inflammation-based assessment for the risk stratification of mortality in patients with heart failure. Sci Rep. 2021; 11(1): 14989.
  26. Kalantar-Zadeh K, Anker SD, Horwich TB, et al. Nutritional and anti-inflammatory interventions in chronic heart failure. Am J Cardiol. 2008; 101(11A): 89E–89103E.
  27. Adamo L, Rocha-Resende C, Prabhu SD, et al. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol. 2020; 17(5): 269–285.
  28. Czapla M, Juárez-Vela R, Łokieć K, et al. The association between nutritional status and in-hospital mortality among patients with heart failure-a result of the retrospective Nutritional Status Heart Study 2 (NSHS2). Nutrients. 2021; 13(5).
  29. Kwaśny A, Uchmanowicz I, Juárez-Vela R, et al. Sex-Related differences in the impact of nutritional status on in-hospital mortality in heart failure: a retrospective cohort study. Eur J Cardiovasc Nurs. 2023 [Epub ahead of print].
  30. Hirose S, Miyazaki S, Yatsu S, et al. Impact of the geriatric nutritional risk index on in-hospital mortality and length of hospitalization in patients with acute decompensated heart failure with preserved or reduced ejection fraction. J Clin Med. 2020; 9(4).
  31. Hersberger L, Dietz A, Bürgler H, et al. Individualized nutritional support for hospitalized patients with chronic heart failure. J Am Coll Cardiol. 2021; 77(18): 2307–2319.
  32. Sobieszek G, Powrózek T, Jaroszyński A, et al. Soluble ST2 proteins in male cachectic patients with chronic heart failure. Nutr Metab Cardiovasc Dis. 2021; 31(3): 886–893.
  33. Yamamoto M, Seo Y, Ishizua T, et al. Comparison of soluble ST2, pentraxin-3, galectin-3, and high-sensitivity troponin t of cardiovascular outcomes in patients with acute decompensated heart failure. J Card Fail. 2021; 27(11): 1240–1250.
  34. Dong CH, Chen SY, Zeng HL, et al. Geriatric nutritional risk index predicts all-cause mortality in patients with heart failure: A systematic review and meta-analysis. Clinics (Sao Paulo). 2021; 76: e2258.
  35. de Ulíbarri IJ, González-Madroño A, González P, et al. CONUT: a tool for controlling nutritional status. First validation in a hospital population. Nutr Hosp. 2005; 20: 38–45.
  36. Takada T, Jujo K, Inagaki K, et al. Nutritional status during hospitalization is associated with the long-term prognosis of patients with heart failure. ESC Heart Fail. 2021; 8(6): 5372–5382.
  37. Komorita T, Yamamoto E, Sueta D, et al. The controlling nutritional status score predicts outcomes of cardiovascular events in patients with heart failure with preserved ejection fraction. Int J Cardiol Heart Vasc. 2020; 29: 100563.
  38. Nishi I, Seo Y, Hamada-Harimura Y, et al. Ibaraki Cardiovascular Assessment Study-Heart Failure Investigators. Utility of nutritional screening in predicting short-term prognosis of heart failure patients. Int Heart J. 2018; 59(2): 354–360.
  39. Dieplinger B, Egger M, Gegenhuber A, et al. Analytical and clinical evaluation of a rapid quantitative lateral flow immunoassay for measurement of soluble ST2 in human plasma. Clin Chim Acta. 2015; 451(Pt B): 310–315.
  40. Galderisi M, Cosyns B, Edvardsen T, et al. 2016–2018 EACVI Scientific Documents Committee, 2016–2018 EACVI Scientific Documents Committee. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2017; 18(12): 1301–1310.
  41. Bouillanne O, Morineau G, Dupont C, et al. Geriatric Nutritional Risk Index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr. 2005; 82(4): 777–783.
  42. Yoshihisa A, Kanno Y, Watanabe S, et al. Impact of nutritional indices on mortality in patients with heart failure. Open Heart. 2018; 5(1): e000730.
  43. Gruson D, Ferracin B, Ahn SA, et al. Soluble ST2, the vitamin D/PTH axis and the heart: New interactions in the air? Int J Cardiol. 2016; 212: 292–294.
  44. Shirakabe A, Hata N, Kobayashi N, et al. The prognostic impact of malnutrition in patients with severely decompensated acute heart failure, as assessed using the Prognostic Nutritional Index (PNI) and Controlling Nutritional Status (CONUT) score. Heart Vessels. 2018; 33(2): 134–144.
  45. Kato T, Yaku H, Morimoto T, et al. Association with Controlling Nutritional Status (CONUT) score and In-hospital mortality and Infection in acute heart failure. Sci Rep. 2020; 10(1): 3320.
  46. Yasumura K, Abe H, Iida Y, et al. Prognostic impact of nutritional status and physical capacity in elderly patients with acute decompensated heart failure. ESC Heart Fail. 2020; 7(4): 1801–1808.
  47. Sze S, Pellicori P, Zhang J, et al. The impact of malnutrition on short-term morbidity and mortality in ambulatory patients with heart failure. Am J Clin Nutr. 2021; 113(3): 695–705.
  48. Sugano A, Seo Y, Ishizu T, et al. Soluble ST2 and brain natriuretic peptide predict different mode of death in patients with heart failure and preserved ejection fraction. J Cardiol. 2019; 73(4): 326–332.
  49. Kaluzna-Oleksy M, Sawczak F, Kukfisz A, et al. Appetite and nutritional status as potential management targets in patients with heart failure with reduced ejection fraction-the relationship between echocardiographic and biochemical parameters and appetite. J Pers Med. 2021; 11(7).
  50. Miller AM, Purves D, McConnachie A, et al. Soluble ST2 associates with diabetes but not established cardiovascular risk factors: a new inflammatory pathway of relevance to diabetes? PLoS One. 2012; 7(10): e47830.
  51. Urban MH, Stojkovic S, Demyanets S, et al. Soluble ST2 and all-cause mortality in patients with chronic obstructive pulmonary disease - a 10-year cohort study. J Clin Med. 2021; 11(1).
  52. Obradovic DM, Büttner P, Rommel KP, et al. Soluble ST2 receptor: biomarker of left ventricular impairment and functional status in patients with inflammatory cardiomyopathy. Cells. 2022; 11(3).
  53. Yucel O, Gul I, Zararsiz A, et al. Association of soluble ST2 with functional capacity in outpatients with heart failure. Herz. 2018; 43(5): 455–460.
  54. Arundel C, Lam PH, Gill GS, et al. Systolic blood pressure and outcomes in patients with heart failure with reduced ejection fraction. J Am Coll Cardiol. 2019; 73(24): 3054–3063.
  55. Kałużna-Oleksy M, Kukfisz A, Migaj J, et al. A simple risk score based on routine clinical parameters can predict frailty in hospitalized heart failure patients. J Clin Med. 2021; 10(24).
  56. Ho JE, Enserro D, Brouwers FP, et al. Predicting heart failure with preserved and reduced ejection fraction: the international collaboration on heart failure subtypes. Circ Heart Fail. 2016; 9(6).
  57. Stolfo D, Uijl A, Vedin O, et al. Sex-based differences in heart failure across the ejection fraction spectrum: phenotyping, and prognostic and therapeutic implications. JACC Heart Fail. 2019; 7(6): 505–515.